TB-500 Research

TB-500 and Thymosin Beta-4 are not the same molecule. TB-500 is a synthetic seven-amino-acid peptide, N-acetyl-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ). It corresponds to residues 17 to 23 of Thymosin Beta-4 (CAS 885340-08-9, PubChem CID 62707662, C38H68N10O14, molecular weight 889.02 Da). Thymosin Beta-4 (Tβ4) is the full-length 43-amino-acid parent peptide of approximately 4963.44 Da (CAS 77591-33-4), and is a separate product.

Almost all of the published tissue-repair literature summarized below was generated with the full-length parent peptide rather than the fragment. This article therefore reports the Thymosin Beta-4 evidence, and states in each case whether a finding came from the full peptide or from the actin-binding-domain fragment.

This article summarizes what preclinical studies show about Thymosin Beta-4 and tissue repair biology. It covers its structure, the actin-binding domain that the commercial compound is built on, the mechanisms it engages, and the cell and animal findings reported to date. It is written for researchers and informed readers, and throughout it states whether a finding comes from a cell culture or an animal model. It describes what research has investigated rather than any outcome a reader should expect. TB-500 is a research compound and is not characterized here for human use.

What TB-500 is, and how it relates to Thymosin Beta-4

A clear identity statement is needed before anything else, because the naming in this area is loose. Thymosin Beta-4 is a defined, naturally occurring 43-amino-acid peptide found across many tissues. TB-500 is a designation used in the research-chemical market rather than a formal pharmacological name.

TB-500 is a defined compound. High-resolution mass spectrometry of commercial TB-500 identified it as the N-terminally acetylated 17-23 fragment of human Thymosin Beta-4, Ac-LKKTETQ. (Esposito et al. Drug Test Anal. 2012;4(9):733-738. PMID 22962027.) That span covers Tβ4 residues 17 to 23, the same fragment used in the published active-site work. Chemical registries index TB-500 under CAS 885340-08-9 / PubChem CID 62707662 as Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH.

The material referred to here is that seven-residue fragment, and full-length 43-amino-acid Thymosin Beta-4 is stocked separately. The name is nonetheless applied loosely elsewhere in the research-chemical market, sometimes by other suppliers to the full-length peptide. The lot certificate of analysis is what settles which compound a given preparation contains.

The substantive peer-reviewed evidence in this field is evidence on Thymosin Beta-4 itself and on defined synthetic peptides containing its actin-binding domain. This article is written on that basis, and it flags where the fragment-versus-full-length distinction matters.

Thymosin Beta-4 structure and the actin-binding domain

Thymosin Beta-4 is a small, acidic, highly conserved peptide of the beta-thymosin family, roughly 4.9 kDa in mass. As reviewed by Goldstein, Hannappel and Kleinman in 2005, its principal intracellular role is as the major G-actin sequestering molecule in eukaryotic cells, where it binds monomeric (globular) actin and thereby helps regulate the assembly and disassembly of the actin cytoskeleton.^[1] This actin-handling function is central to cell shape and movement.

The actin-binding activity localizes to a short internal sequence, and the conserved actin-binding motif is the hexapeptide LKKTET, spanning residues 17 to 22. The peptide actually used in the fragment literature, and the peptide sold as TB-500, is the seven-residue span 17 to 23, LKKTETQ, which adds the adjacent glutamine. Philp and colleagues and Sosne and colleagues both define the active fragment on that seven-residue basis.

Mutational mapping by Van Troys and colleagues in 1996, carried out on chemically synthesized full-length Thymosin Beta-4 variants rather than on isolated fragments, showed that actin binding depends on two separate structural regions. The first region is an N-terminal segment (residues 1 to 16) that must adopt an alpha-helix and contacts actin through a hydrophobic patch. The second is the 17 to 22 motif, and charged and hydrophobic residues in both regions participate. Electrostatic contacts from lysine 18 in the motif and lysine 14 in the N-terminal helix were identified as important.^[2] The isolated motif was not tested in that study. Its affinity on its own therefore cannot be read from it.

Later active-site work found that distinct short fragments carry distinct activities, with the region around residues 17 to 23, which contains the actin-binding motif, being the part associated with cell migration, actin binding, angiogenesis and dermal repair in laboratory studies.^[3]

Mechanisms relevant to tissue repair

Several mechanisms have been proposed from in vitro and animal work, and most trace back to actin regulation.

The first is cell migration. By regulating actin dynamics, Thymosin Beta-4 has been associated with increased migration of several cell types important to repair, including endothelial cells and keratinocytes.

The second is angiogenesis, the formation of new blood vessels. Philp and colleagues reported in 2003 that the actin-binding site of the peptide itself promotes angiogenesis in laboratory assays.^[4]

The third is cell survival signaling. In the cardiac setting, Bock-Marquette and colleagues found in 2004 that Thymosin Beta-4 formed a functional complex with the proteins PINCH and integrin-linked kinase (ILK). They reported that this complex formation led to activation of the survival kinase Akt.^[5]

A fourth strand concerns modulation of inflammation, and a 2010 review by Sosne and colleagues assigns anti-inflammatory and anti-fibrotic activity to the four-residue N-terminal fragment Ac-SDKP. The same review assigns anti-apoptotic, pro-survival activity to a 15-residue N-terminal segment.^[3] Neither of these regions is present in the 17 to 23 fragment sold as TB-500. These activities are therefore attributes of the full-length peptide and of separate N-terminal peptides, not of TB-500.

All of these are cellular or animal findings.

Preclinical research overview

Dermal wound models

The dermal evidence is among the most direct. Malinda and colleagues reported in 1999 that, in a rat full-thickness wound model, Thymosin Beta-4 applied topically or systemically increased re-epithelialization and wound contraction relative to saline controls.^[6]

Later work extended testing to impaired-healing animal models. Philp and colleagues reported in 2003 that full-length Thymosin Beta-4 accelerated dermal wound repair in db/db diabetic mice and in 26-month-old aged mice. The same 2003 report also found that a seven-amino-acid synthetic peptide reproducing the actin-binding domain, LKKTETQ, promoted repair in the aged animals comparably to the parent molecule. LKKTETQ is the same seven-residue sequence that TB-500 supplies in N-acetylated form. No result for the fragment in the diabetic model was reported. (Philp D, Badamchian M, Scheremeta B, Nguyen M, Goldstein AL, Kleinman HK. Wound Repair Regen. 2003;11(1):19-24. PMID 12581423.) These are animal model results.

Cardiac and vascular models

In the heart, the 2004 mouse study above reported that, after experimental coronary artery ligation, Thymosin Beta-4 treatment was associated with increased ILK and Akt activity. Treatment was also associated with enhanced early myocyte survival and improved cardiac function in the model.^[5] Smart and colleagues reported in 2007 that Thymosin Beta-4 could mobilize adult epicardial progenitor cells and promote neovascularization in mice.^[7] Both findings are from animal models.

Fragment and actin-binding-domain peptides

This strand is most relevant to the TB-500 designation. Philp and colleagues in 2003 showed that activity does not require the entire 43-residue peptide. The seven-amino-acid actin-binding motif matched full-length Thymosin Beta-4 in human umbilical vein endothelial cell migration and chick aortic-arch sprouting assays at around 50 nM. Peptides lacking any portion of the motif were inactive.^[4] Those are cell-culture and ex vivo explant assays, not in vivo animal experiments.

A 2010 review by Sosne and colleagues summarizes the wider active-site literature. It identifies LKKTETQ, residues 17 to 23, as the sequence associated with angiogenesis, wound healing and cell migration.^[3] In vivo evidence for the fragment itself is thinner than for the parent peptide, and the clearest example is the aged-mouse dermal wound work described above.

Human research context

The directly relevant repair-biology evidence is overwhelmingly preclinical, and pharmaceutical development in this area has used full-length 43-amino-acid Thymosin Beta-4, not the seven-residue TB-500 fragment. That is a different molecule from the compound discussed here, and no outcome should be inferred from it. Readers should treat any extrapolation from animal data to humans as unproven.

Limitations and research directions

Several limitations shape how this body of work should be read.

The main limitation for anyone reading this literature is that most of it was generated with full-length 43-amino-acid Thymosin Beta-4 (CAS 77591-33-4). It was not generated with the seven-residue Ac-LKKTETQ fragment sold as TB-500 (CAS 885340-08-9). Of the studies cited here, the cardiac, epicardial and rat dermal work used the full peptide, and only the actin-binding-domain studies used the fragment. Findings obtained with the parent peptide should not be assumed to transfer to the fragment.

A separate practical issue is that the name TB-500 is applied inconsistently across the research-chemical market, sometimes to the full-length peptide. The lot certificate of analysis is what settles which compound a given preparation contains.

Much of the foundational work also originates from a relatively small number of groups, and the proposed mechanisms are multiple and not fully resolved. Human pharmacokinetic and long-term safety data are limited.

Conclusion

TB-500 is best understood as a research designation tied to Thymosin Beta-4 and, in particular, to its actin-binding domain. The science that defines it is the preclinical biology of Tβ4. That is an actin-sequestering peptide associated, in cell and animal models, with cell migration, angiogenesis and survival signaling during tissue repair.

References

1. 1

   Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429. PMID 16099219. .
2. 2

   Van Troys M, Dewitte D, Goethals M, Carlier MF, Vandekerckhove J, Ampe C. The actin binding site of thymosin beta 4 mapped by mutational analysis. EMBO J. 1996;15(2):201-210. PMID 8617195. .
3. 3

   Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J. 2010;24(7):2144-2151. PMID 20179146. .
4. 4

   Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J. 2003;17(14):2103-2105. PMID 14500546. .
5. 5

   Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. PMID 15565145. .
6. 6

   Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, Kleinman HK. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. PMID 10469335. .
7. 7

   Smart N, Risebro CA, Melville AAD, Moses K, Schwartz RJ, Chien KR, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-182. PMID 17108969. .